SLV-324 Treatment of Metastatic Solid Tumors
ConditionMetastatic Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorSolve Therapeutics
About this trial
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.
Eligibility criteria
Qualifiers
Men or women (as appropriate for cancer type) of age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records.
Presence of metastatic disease that has progressed during or following previous treatment.
Disqualifiers
Malignancy involving the central nervous system unless brain metastases have been previously treated with radiotherapy, have been stable for ≥4 weeks, and do not require corticosteroids.
Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
Significant cardiovascular event or comorbidity.
Trial design
Treatments tested in this trial
- SLV-324 intravenous (IV infusion)
Treatment groups
70 Participants
are divided into 1 treatment groupLocations
7California
Hoag Memorial Hospital Presbyterian92663, Newport Beach United States
Missouri
Washington University63110, St Louis United States
Ohio
University Hospitals Cleveland Medical Center44106, Cleveland United States
Pennsylvania
Fox Chase Cancer Center19111, Philadelphia United States
Sponsors and collaborators
Solve Therapeutics
Lead sponsor
Source ClinicalTrials.gov